Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Genprex Inc. (GNPX)

3.36   0.1 (3.07%) 10-01 08:34
Open: 3.29 Pre. Close: 3.26
High: 3.47 Low: 3.27
Volume: 555,661 Market Cap: 131M
Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. The company is headquartered in Austin, Texas and currently employs 7 full-time employees. The firm is focused on developing cancer-based upon its novel proprietary technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. The Company’s Oncoprex is lead product candidate, is the subject of an ongoing Phase I/II clinical trials at The University of Texas MD Anderson Cancer Center in patients with late stage non-small cell lung cancer, or NSCLC. Oncoprex gene therapy platform may also be effective with respect to other types of cancer, including breast, head and neck, renal cell (kidney), soft tissue cancer. The Company’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The Company’s Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.356 - 3.376 3.376 - 3.396
Low: 3.207 - 3.228 3.228 - 3.251
Close: 3.28 - 3.317 3.317 - 3.357

Technical analysis

as of: 2020-09-30 4:42:09 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 4.59     One year: 5.22
Support: Support1: 3.05    Support2: 2.54
Resistance: Resistance1: 3.93    Resistance2: 4.47
Pivot: 3.57
Moving Average: MA(5): 3.31     MA(20): 3.65
MA(100): 3.40     MA(250): 2.28
MACD: MACD(12,26): -0.11     Signal(9): -0.06
Stochastic oscillator: %K(14,3): 27.22     %D(3): 19.82
RSI: RSI(14): 40.49
52-week: High: 7.03  Low: 0.23  Change(%): 356.0
Average Vol(K): 3-Month: 135903  10-Days: 66922

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
GNPX has closed above bottom band by 20.7%. Bollinger Bands are 6.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sat, 26 Sep 2020
What Is Going On With Genprex, Inc. (NASDAQ:GNPX)? - Stocks Register

Fri, 25 Sep 2020
The key reasons why Genprex Inc. (GNPX) is -55.90% away from 52-week high? - News Daemon

Thu, 24 Sep 2020
Roll up the Sleeves! When the bell rang at previous close Genprex Inc. (GNPX) was down -5.88% - investchronicle.com

Thu, 24 Sep 2020
Should You Buy Genprex Inc (GNPX) Stock? - InvestorsObserver

Mon, 21 Sep 2020
Genprex names Thomas C. Gallagher as the company"s senior vice president of Intellectual Property and Licensing - Proactive Investors USA & Canada

Mon, 21 Sep 2020
Genprex, Inc. (NASDAQ:GNPX) Forecast to gain 84.21% to hit Consensus price target - Marketing Sentinel

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 39
Shares Float (M) 32
% Held by Insiders 23.00
% Held by Institutions 12.82
Shares Short (K) 3,810
Shares Short P. Month (K) 3,940

Stock Financials

EPS -0.611
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 0.630
Profit Margin
Operating Margin
Return on Assets (ttm) -59.5
Return on Equity (ttm) -98.8
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.379
Qtrly Earnings Growth
Operating Cash Flow (M) -12
Levered Free Cash Flow (M) -6

Stock Valuations

PE Ratio -5.43
PEG Ratio
Price to Book value 5.27
Price to Sales
Price to Cash Flow -10.99

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.